JP2022535550A5 - - Google Patents

Info

Publication number
JP2022535550A5
JP2022535550A5 JP2021571942A JP2021571942A JP2022535550A5 JP 2022535550 A5 JP2022535550 A5 JP 2022535550A5 JP 2021571942 A JP2021571942 A JP 2021571942A JP 2021571942 A JP2021571942 A JP 2021571942A JP 2022535550 A5 JP2022535550 A5 JP 2022535550A5
Authority
JP
Japan
Prior art keywords
cells
macrophages
bone marrow
marrow cells
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535550A (ja
JP7716992B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035702 external-priority patent/WO2020247371A1/en
Publication of JP2022535550A publication Critical patent/JP2022535550A/ja
Publication of JP2022535550A5 publication Critical patent/JP2022535550A5/ja
Priority to JP2025107222A priority Critical patent/JP2025129213A/ja
Application granted granted Critical
Publication of JP7716992B2 publication Critical patent/JP7716992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571942A 2019-06-04 2020-06-02 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用 Active JP7716992B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107222A JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962857169P 2019-06-04 2019-06-04
US62/857,169 2019-06-04
US201962867569P 2019-06-27 2019-06-27
US62/867,569 2019-06-27
US201962947948P 2019-12-13 2019-12-13
US62/947,948 2019-12-13
US202063032214P 2020-05-29 2020-05-29
US63/032,214 2020-05-29
PCT/US2020/035702 WO2020247371A1 (en) 2019-06-04 2020-06-02 Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107222A Division JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Publications (3)

Publication Number Publication Date
JP2022535550A JP2022535550A (ja) 2022-08-09
JP2022535550A5 true JP2022535550A5 (cg-RX-API-DMAC7.html) 2023-06-12
JP7716992B2 JP7716992B2 (ja) 2025-08-01

Family

ID=73651973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571942A Active JP7716992B2 (ja) 2019-06-04 2020-06-02 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用
JP2025107222A Pending JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107222A Pending JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Country Status (11)

Country Link
US (1) US12552873B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980463A4 (cg-RX-API-DMAC7.html)
JP (2) JP7716992B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220042055A (cg-RX-API-DMAC7.html)
CN (1) CN114401990A (cg-RX-API-DMAC7.html)
AU (1) AU2020288823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024242A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141334A1 (cg-RX-API-DMAC7.html)
IL (1) IL288510A (cg-RX-API-DMAC7.html)
TW (1) TW202110891A (cg-RX-API-DMAC7.html)
WO (1) WO2020247371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
KR20220042055A (ko) 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US12682015B2 (en) * 2021-03-03 2026-07-14 International Business Machines Corporation Ensemble voting classifiers using adjusted thresholds
JP2024540484A (ja) * 2021-11-17 2024-10-31 アルトゥルバイオ, インコーポレイテッド 抗psgl-1抗体をjak阻害剤と組み合わせて使用してt細胞媒介性炎症性疾患またはがんを治療する方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
CN120682308B (zh) * 2025-06-23 2025-12-02 北京昌盛鸿途生物科技有限公司 牛骨髓肽及其在提高免疫力中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362227A1 (en) 2000-03-24 2004-10-18 Genetic Institute, Llc A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
KR20060107501A (ko) * 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
CA2561835A1 (en) 2004-03-30 2005-10-13 Den Kgl. Veterinaer-Og Landbohojskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
AU2009246166B2 (en) 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
WO2011143411A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US20120130603A1 (en) 2010-11-18 2012-05-24 Sean Michael Simpson System and method for controlling a transmission of a human-powered vehicle
EP3222635A1 (en) * 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
EP2718325A4 (en) * 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR102061358B1 (ko) 2011-10-21 2019-12-31 트랜스진 에스.에이. 대식세포 활성화의 조절
WO2015077401A1 (en) 2013-11-20 2015-05-28 Drexel University Compositions and methods for macrophage conversion
EP4079324A1 (en) * 2014-07-08 2022-10-26 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
WO2016033527A1 (en) 2014-08-29 2016-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
GB201611535D0 (en) 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
WO2020006385A2 (en) 2018-06-29 2020-01-02 Verseau Therapeutics, Inc. Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
KR20220042055A (ko) 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도

Similar Documents

Publication Publication Date Title
JP2022535417A5 (cg-RX-API-DMAC7.html)
US20240082307A1 (en) Diagnostic methods for t cell therapy
Thistlethwaite et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
ES2961666T3 (es) Métodos para determinar la dosificación de células CAR-T
JP6788629B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
JP2022540768A5 (cg-RX-API-DMAC7.html)
CN107438621B (zh) 抗pd-1抗体
JP2023527410A5 (cg-RX-API-DMAC7.html)
KR20200116081A (ko) 유전자 조작된 세포의 투약 및 조절 방법
JP2021521137A (ja) 腫瘍微小環境の特性を使用するキメラ受容体t細胞治療
WO2019222188A1 (en) Methods of treating cancer
JP2019513400A (ja) エクスビボのbite活性化t細胞
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
KR20190117014A (ko) 방광암의 항-pd-l1 항체 치료
WO2019232479A2 (en) Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
JP2022539038A5 (cg-RX-API-DMAC7.html)
JP2023501487A (ja) 白血球上での細胞表面マーカーの発現を制御するための抗Clever-1剤、および抗Clever-1に基づくがん治療を導くためのこれらの使用
EP3388073A1 (en) Targeting mesothelin in brain cancer
US20240158869A1 (en) Factors for optimizing immunotherapy
US20250161361A1 (en) Factors for optimizing immunotherapy efficacy
JP2026510915A (ja) 免疫療法の有効性に対する腫瘍微小環境の影響
WO2026096859A2 (en) Biomarkers related to immunotherapy efficacy
WO2025199220A1 (en) Post-infusion predictors of car t-cell therapy response
WO2024218318A1 (en) Markers for predicting therapeutic efficacy of a t cell